{
  "docId": "019de072-468c-700c-89db-ca818deece7f",
  "docSlug": "40fd19b5105eee76fe8edee20250e12b",
  "documentTitle": "AN2 Therapeutics | IPO Presentation Deck | 27 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 22,
  "pageCount": 27,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 28,
  "notes": "The table uses checkmarks and X marks to highlight competitive advantages of EBO.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-468c-700c-89db-ca818deece7f/22",
  "deckHref": "/decks/019de072-468c-700c-89db-ca818deece7f",
  "deckJsonHref": "/decks/019de072-468c-700c-89db-ca818deece7f.json",
  "deckAnchorHref": "/decks/019de072-468c-700c-89db-ca818deece7f#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.3,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "TPP criteria and product profiles presented in this table are based on an in-house analysis of published data, drug product labeling, and have been combined from multiple sources presented in different studies.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9126231c-ecd8-4c41-b271-492b08eedf81",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.3,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "1. Wu ML, Aziz DB, Dartois V, Dick T. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018;23(8):1502-1519. 2. Spero Therapeutics. 3. Redhill Biopharma.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8715e7a5-72af-4138-989e-ec1497e87b74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.8,
        "w": 0.65,
        "x": 0.3,
        "y": 0.05
      },
      "kind": "table",
      "text": "Planned Target Product Profile (TPP) Criteria. EBO vs ARIKAYCE, SPR-720, RHB-204 across 7 criteria.",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84c9a86a-342b-445b-8587-3e6d97aaa255",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Attractive target product profile to address unmet needs in NTM with potential to become an important component of therapy",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69203a27-3eaf-4131-9e62-18a6b66a1678",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "1b010dca-3f89-4c32-bc0e-f4379995a208",
      "evidence": "Table/comparison: Planned Target Product Profile (TPP) Criteria",
      "confidence": 0.5
    },
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "30b72b28-11a0-43bd-973b-d0b6b479fd38",
      "evidence": "Planned Target Product Profile (TPP) Criteria. EBO vs ARIKAYCE, SPR-720, RHB-204 across 7 criteria.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "25edce7e-18b5-4fcc-bc3e-8a0cab7165d0",
      "evidence": "Comparison table of product features against competitors",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 27,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "5c43fe0e-f0f3-4ff4-8709-c2c99c61b351",
      "evidence": "The deck starts and ends with the company's mission",
      "position": 1,
      "objective": "Present a clear mission and vision for AN2 Therapeutics",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}